Literature DB >> 24631737

Cytotoxic T-lymphocyte antigen-4 single nucleotide polymorphisms are not associated with outcomes after unrelated donor transplantation: a center for international blood and marrow transplant research analysis.

Salyka Sengsayadeth1, Tao Wang2, Stephanie J Lee3, Michael D Haagenson4, Stephen Spellman4, Marcelo A Fernandez Viña5, Carlheinz R Muller6, Michael R Verneris7, Bipin N Savani8, Madan Jagasia8.   

Abstract

Cytotoxic T-lymphocyte antigen-4 (CTLA-4) plays an essential role in T cell homeostasis by restraining immune responses. AG and GG genotypes of donor CTLA-4 SNP rs4553808 in patients after unrelated donor hematopoietic stem cell transplantations (HSCT) have been shown to be an independent predictor of inferior relapse-free survival (RFS) and overall survival (OS) compared with those with the AA genotype, in single-center studies. We tested the hypothesis that SNP rs4553808 is associated with RFS, OS, nonrelapse mortality (NRM) and the cumulative incidence of acute graft-versus-host disease (GVHD) and chronic GVHD in adults with acute myeloid leukemia and advanced myelodysplastic syndrome undergoing a first 8/8 or 7/8 HLA-matched unrelated donor HSCT. Multivariable analysis adjusting for relevant donor and recipient characteristics showed no significant association between SNP rs4553808 and OS, RFS, NRM, and incidence of acute and chronic GVHD. An exploratory analysis of other CTLA-4 SNPs, as well as studying the interaction with antithymocyte globulin, also demonstrated no significant associations. Our results indicate that CTLA-4 SNPs are not associated with HSCT outcomes. Published by Elsevier Inc.

Entities:  

Keywords:  Cytotoxic T-lymphocyte antigen-4 (CTLA-4); Hematopoietic stem cell transplantation; Single nucleotide polymorphisms (SNPs)

Mesh:

Substances:

Year:  2014        PMID: 24631737      PMCID: PMC4034271          DOI: 10.1016/j.bbmt.2014.03.005

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  14 in total

1.  Donor CTLA-4 +49 A/G*GG genotype is associated with chronic GVHD after HLA-identical haematopoietic stem-cell transplantations.

Authors:  Mariam Azarian; Marc Busson; Virginia Lepage; Dominique Charron; Antoine Toubert; Pascale Loiseau; Regis Peffault de Latour; Vanderson Rocha; Gerard Socié
Journal:  Blood       Date:  2007-12-15       Impact factor: 22.113

2.  Significance of CTLA-4 and CD14 genetic polymorphisms in clinical outcome after allogeneic stem cell transplantation.

Authors:  A M Vannucchi; S Guidi; P Guglielmelli; S Glinz; L Lombardini; A Busca; F Locatelli; A M Dall'Omo; A Bosi
Journal:  Bone Marrow Transplant       Date:  2007-09-10       Impact factor: 5.483

3.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

Review 4.  Genomic studies of GVHD-lessons learned thus far.

Authors:  C Ting; G Alterovitz; A Merlob; R Abdi
Journal:  Bone Marrow Transplant       Date:  2012-02-20       Impact factor: 5.483

5.  CTLA-4 polymorphisms and clinical outcome after allogeneic stem cell transplantation from HLA-identical sibling donors.

Authors:  Arianne Pérez-García; Rafael De la Cámara; Jose Román-Gómez; Antonio Jiménez-Velasco; Maite Encuentra; Jose B Nieto; Javier de la Rubia; Alvaro Urbano-Ispizúa; Salut Brunet; Arturo Iriondo; Marcos González; David Serrano; Ildefonso Espigado; Carlos Solano; Josep M Ribera; Josep M Pujal; Montserrat Hoyos; David Gallardo
Journal:  Blood       Date:  2007-03-23       Impact factor: 22.113

6.  Effect of donor CTLA-4 alleles and haplotypes on graft-versus-host disease occurrence in Tunisian patients receiving a human leukocyte antigen-identical sibling hematopoietic stem cell transplant.

Authors:  Mohamed Hichem Sellami; Meriem Bani; Lamia Torjemane; Houda Kaabi; Saloua Ladeb; Tarek Ben Othmane; Slama Hmida
Journal:  Hum Immunol       Date:  2010-11-13       Impact factor: 2.850

7.  Cytotoxic T-lymphocyte-associated antigen-4.

Authors:  April K S Salama; F Stephen Hodi
Journal:  Clin Cancer Res       Date:  2011-04-05       Impact factor: 12.531

8.  Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade.

Authors:  Willemijn B Breunis; Eduardo Tarazona-Santos; Renee Chen; Maureen Kiley; Steven A Rosenberg; Stephen J Chanock
Journal:  J Immunother       Date:  2008 Jul-Aug       Impact factor: 4.456

Review 9.  A molecular perspective of CTLA-4 function.

Authors:  Wendy A Teft; Mark G Kirchhof; Joaquín Madrenas
Journal:  Annu Rev Immunol       Date:  2006       Impact factor: 28.527

Review 10.  Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond.

Authors:  M Mohty
Journal:  Leukemia       Date:  2007-04-05       Impact factor: 11.528

View more
  5 in total

1.  Replication and validation of genetic polymorphisms associated with survival after allogeneic blood or marrow transplant.

Authors:  Ezgi Karaesmen; Abbas A Rizvi; Leah M Preus; Philip L McCarthy; Marcelo C Pasquini; Kenan Onel; Xiaochun Zhu; Stephen Spellman; Christopher A Haiman; Daniel O Stram; Loreall Pooler; Xin Sheng; Qianqian Zhu; Li Yan; Qian Liu; Qiang Hu; Amy Webb; Guy Brock; Alyssa I Clay-Gilmour; Sebastiano Battaglia; David Tritchler; Song Liu; Theresa Hahn; Lara E Sucheston-Campbell
Journal:  Blood       Date:  2017-08-15       Impact factor: 22.113

Review 2.  Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia.

Authors:  Hanna A Knaus; Christopher G Kanakry; Leo Luznik; Ivana Gojo
Journal:  Curr Drug Targets       Date:  2017       Impact factor: 3.465

Review 3.  Identification and utilization of donor and recipient genetic variants to predict survival after HCT: are we ready for primetime?

Authors:  Lara E Sucheston-Campbell; Alyssa Clay; Philip L McCarthy; Qianqian Zhu; Leah Preus; Marcelo Pasquini; Kenan Onel; Theresa Hahn
Journal:  Curr Hematol Malig Rep       Date:  2015-03       Impact factor: 3.952

Review 4.  The prognostic value of cytotoxic T-lymphocyte antigen 4 in cancers: a systematic review and meta-analysis.

Authors:  Pingping Hu; Qiqi Liu; Guodong Deng; Jingxin Zhang; Ning Liang; Jian Xie; Jiandong Zhang
Journal:  Sci Rep       Date:  2017-02-17       Impact factor: 4.379

Review 5.  The Role of CTLA4 and Its Polymorphisms in Solid Organ and Haematopoietic Stem Cell Transplantation.

Authors:  Jakub Rosik; Bartosz Szostak; Filip Machaj; Andrzej Pawlik
Journal:  Int J Mol Sci       Date:  2021-03-17       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.